{
    "2018-05-01": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today",
                "features": {
                    "keywords": [
                        "Nutrisystem",
                        "Tenet Healthcare",
                        "AbbVie",
                        "Jumped"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Seagate, Pfizer and Cummins skid while AbbVie jumps",
                "features": {
                    "keywords": [
                        "Seagate",
                        "Pfizer",
                        "Cummins",
                        "skid",
                        "AbbVie",
                        "jumps"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "industrial"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie’s Hepatitis C Franchise, Kaletra, and Synagis in 1Q18",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Hepatitis C",
                        "Kaletra",
                        "Synagis",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector",
                "features": {
                    "keywords": [
                        "Stocks",
                        "selling off",
                        "ISM miss",
                        "factory sector"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "manufacturing"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie’s Humira and Imbruvica: 1Q18 Performance",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Humira",
                        "Imbruvica",
                        "1Q18"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "How AbbVie Fared in 1Q18",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "How AbbVie Makes its Money",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Money"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Pre-Market Most Active for May 1, 2018 : BP, TVIX, QQQ, SNE, SHOP, AAPL, ABBV, UAA, KLXI, UA, AVXS, SQQQ",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Most Active",
                        "BP",
                        "TVIX",
                        "QQQ",
                        "SNE",
                        "SHOP",
                        "AAPL",
                        "ABBV",
                        "UAA",
                        "KLXI",
                        "UA",
                        "AVXS",
                        "SQQQ"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "energy",
                        "technology",
                        "healthcare",
                        "retail"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Marketing Authorization",
                        "European Medicines Agency",
                        "Risankizumab",
                        "Plaque Psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Self-Tender Offer",
                        "$7.5 Billion",
                        "Common Stock"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "[$$] Gilead shares rattled by sharp slide in hepatitis C drug sales",
                "features": {
                    "keywords": [
                        "Gilead",
                        "shares",
                        "rattled",
                        "hepatitis C",
                        "drug sales"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}